Intracavernosal Injection and Intraurethral Therapy for Erectile Dysfunction
Overview
Authors
Affiliations
Although the search for newer and more effective oral therapies is continually expanding, intracavernosal and intraurethral treatments continue to keep pace and are expected to remain in the clinician's armamentarium in the years to come. Unless there are contraindications, oral therapies are effective, have minimal side effects, and are first-line treatment. Some patients who have failed intraurethral and intracavernosal injection therapies previously have been shown to have successful outcomes with oral sildenafil in 56% to 57% of cases. If oral therapies are ineffective or have undesirable side effects, the intraurethral or intracavernosal routes are the next approach that should be prescribed.
Park N, Kim S, Hwang S, Park H Investig Clin Urol. 2019; 60(4):275-284.
PMID: 31294137 PMC: 6607068. DOI: 10.4111/icu.2019.60.4.275.
Park H, Kim S, Kim J, Lee S, Paick J, Ahn T J Korean Med Sci. 2017; 32(6):1016-1023.
PMID: 28480661 PMC: 5426242. DOI: 10.3346/jkms.2017.32.6.1016.
[Side effects of erectile dysfunction drug treatment].
Sperling H Urologe A. 2017; 56(4):451-455.
PMID: 28251255 DOI: 10.1007/s00120-017-0341-4.
Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction.
Ryu J, Cho K, Kim S, Oh K, Kam S, Seo K World J Mens Health. 2013; 31(2):83-102.
PMID: 24044105 PMC: 3770856. DOI: 10.5534/wjmh.2013.31.2.83.
Looking to the future for erectile dysfunction therapies.
Hatzimouratidis K, Hatzichristou D Drugs. 2008; 68(2):231-50.
PMID: 18197727 DOI: 10.2165/00003495-200868020-00006.